COMPANY PROFILE

Perfuze

Explore full profile

Neurovascular medical device company developing technology for Ischemic Stroke

Galway, IrelandFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Perfuze

Perfuze, a Galway-based medical device company, is advancing fast, safe, and predictable stroke treatment through innovation.

Backed by the MARRS trial clinical evidence, the Millipede™ System’s unique corrugated design offers best-in-class deliverability and precise vessel matching for superior first-pass success.

Combining powerful aspiration with reliable performance, the Perfuze portfolio helps physicians restore blood flow quickly and safely.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Galway, Ireland
Employees: 46
Open positions: None listed
Dealroom signal: 85.0/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Medical Research, Research and Development, Neurology, Medical Systems, Clinical Trials, biotech medtech and e-health, Horizon Europe, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Mar 2025	$24M	$97M	Earlybird Venture Capital · Seroba Life Sciences · EQT Life Sciences · SV Health Investors	↗
SERIES AOther financing	Feb 2022	$25M	$99M	Earlybird Venture Capital · HBM-MedFocus · EQT Life Sciences · Enterprise Ireland	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	EBITDA	Margin
2026		—
2025		—
2024		—
2023		—
2022		—
2021		—
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Perfuze website traffic

Latest recorded traffic for Perfuze is 1.3K monthly website visits, down 23.5% over the last three months. Perfuze's team grew 4.5% over the past year.

Latest monthly visits1.3K 3-month web change-23.5% 1-year team growth+4.5%

Monthly website visitsFeb 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RMRelevium MedicalDeveloping novel pharmacological hydrogel treatments for chronic pain conditions in urgent need of superior solutions.	Galway, Ireland	Operational	2	$5.2M	$500K
UNUlysses NeuroscienceYour vanguard CRO and translational partner	Dublin, Ireland	Operational
LMLatch MedicalA new approach to drug and vaccine delivery	Dublin, Ireland	Operational
AGAgenTDeveloping the first blood diagnosis to detect Alzheimer’s disease while it’s still in the silent phase	Paris, France	Operational
OWOwkinCollaborative research platform and unique AI drug development solutions that make precision medicine a reality	Paris, France	Operational
IBInSoma BioElastin-based biomaterial scaffold for fat, enabling better soft tissue reconstruction procedures	Durham, United States	Operational
ENEnteraSenseThe first and only FDA approved capsule for rapid detection of upper GI bleeding.	Galway, Ireland	Operational
MTMauna Kea TechnologiesReal-time in vivo cellular imaging platform.	Paris, France	Operational